Mission Bio · Tapestri Platform
Gene Expression
Reference Target Portfolio
Reference Target Portfolio
Single-Cell Multi-Omics · Targeted Transcriptomics · 2026
24 Panels
4 Disease Categories
152 – 306 Targets / Group
7 Functional Categories Each
| Disease / Application | Unique Genes | Func. Categories | Functional Categories (genes per category) | Flyer |
|---|---|---|---|---|
| Hematologic Malignancies 7 panels | ||||
|
Acute Lymphoblastic Leukemia (ALL)
B-ALL · T-ALL · Ph+ ALL
|
242 | 7 | Driver / Ph / Ph-like Fusions 52Lymphoid Lineage / Subtype 50CAR-T Antigens / Surface 42Immune Evasion / MRD 40T-ALL / NOTCH1 Axis 40Cell Cycle / Apoptosis 24Epigenetic / Splicing 20 | View ↗ |
|
AML / MDS
AML · MDS · MPN
|
276 | 7 | Driver Mutations & Oncogenic Signaling 66Cell State / Differentiation Hierarchy 45Proliferation / Cell Cycle 28Apoptosis / Therapy Resistance 39Immune Microenvironment 58Cytokine / Niche Signaling 26Epigenetic / Splicing / DNA Repair 37 | View ↗ |
|
Myeloproliferative Neoplasms (MPN)
ET · PV · MF
|
222 | 7 | JAK-STAT / Driver 45Cytokine / Fibrosis 82HSC / Myeloid 32Immune / BM 16Resistance 34Cell Cycle 9Epigenetic 13 | View ↗ |
|
Multiple Myeloma
Newly Diagnosed MM · RRMM · High-Risk (del17p / t(4;14))
|
232 | 7 | Plasma Cell Identity & Drivers 90Bone Marrow Niche 19Immune Microenvironment 23Drug Resistance 22Proliferation 48Apoptosis / BCL-2 9DNA Damage / Epigenetics 34 | View ↗ |
|
Non-Hodgkin Lymphoma (NHL)
DLBCL (GCB / ABC) · Follicular Lymphoma · MCL
|
253 | 7 | B Cell Oncogenic Signaling 64Immune Microenvironment 60B Cell Identity & Differentiation 45Epigenetic / Chromatin 35Proliferation / Cell Cycle 32Apoptosis / Therapy Resistance 35DNA Damage / Genomic Stability 29 | View ↗ |
|
B-Cell Lymphoma (BCL)
DLBCL (GCB / ABC) · FL · MCL · MZL · Burkitt
|
189 | 7 | COO / Oncogenic Signaling 64Immune Microenvironment 56B-Cell Identity & Subtype 54Epigenetic / Chromatin 38Proliferation / Cell Cycle 35Apoptosis / Therapy Resistance 35DNA Damage / Translocation 28 | View ↗ |
|
Multiple Sclerosis
RRMS · PPMS · SPMS
|
230 | 7 | T Cell / Autoimmune Pathways 52B Cell / Plasma Cell 38Microglia / CNS Innate 42Oligodendrocyte / Remyelination 42Astrocyte / Neuroinflammation 38Therapy Targets 28Cytokines / Complement 24 | View ↗ |
| Solid Tumors 12 panels | ||||
|
Bladder Cancer
NMIBC · MIBC · UC
|
256 | 7 | Driver / FGFR3 / PIK3CA 48Lineage / MIBC Subtypes 52Immune TME 52DDR / Cisplatin Sensitivity 32Stroma / EMT 38Cell Cycle 24Metabolism 19 | View ↗ |
|
Brain Cancer / Glioma
GBM · IDH-mutant Glioma · Pediatric GBM
|
239 | 7 | IDH / Driver Oncogenes 52Glioma Cell States 63Immune Microenvironment 52Proliferation / Cell Cycle 28Epigenetic / MGMT 28Invasion / Angiogenesis 28WHO Lineage / Stem Identity 30 | View ↗ |
|
Breast Cancer
HR+ · HER2+ · TNBC
|
278 | 7 | Hormone Receptor & HER2 116DNA Damage / HRD 21Immune Microenvironment 74Stromal / Angiogenesis 18Proliferation / Cell Cycle 13AR / Metabolism 9Cell State / Lineage 32 | View ↗ |
|
Colorectal Cancer (CRC)
Colorectal Cancer · Solid Tumor · Multi-pathway
|
255 | 7 | Tumor Intrinsic Signaling 59Cell State / Differentiation 31Proliferation / Cell Cycle 30EMT / Invasion 27Immune Microenvironment 52Stromal / Angiogenesis 28DNA Damage / Genomic Stability 34 | View ↗ |
|
Endometrial Cancer
MSI-H · POLE-ultramutated · p53-mutant
|
232 | 7 | TCGA Molecular Subtypes / Driver 48MMR / POLE / TMB 42HER2 / PI3K Pathway 40Immune TME / Checkpoint 48Lineage / Histotype 36Stroma / EMT 28Cell Cycle 20 | View ↗ |
|
Hepatocellular Carcinoma (HCC)
HCC · Cholangiocarcinoma · Combined HCC-ICC
|
232 | 7 | Driver / CTNNB1 / TERT 52VEGF / Angiogenesis 38Immune TME 52Fibrotic Stroma / HSC 40Lineage / HCC Subtypes 38Cell Cycle 22Metabolism / Lipid 20 | View ↗ |
|
Head & Neck Cancer (HNSCC)
HPV+ Oropharynx · HPV− HNSCC · Oral Cavity
|
240 | 7 | Driver / EGFR / PI3K 52Squamous Lineage / Subtype 48Immune TME / Checkpoint 52HPV+ Biology 32Stroma / EMT 38Cell Cycle 24DDR / HRD 19 | View ↗ |
|
Melanoma
Cutaneous · Acral · Mucosal
|
251 | 7 | MAPK Driver Signaling 63Immune Microenvironment 66MAPKi Resistance 39MHC-I & Antigen Presentation 31Stromal / Angiogenesis 33Proliferation / Cell Cycle 30DNA Damage / UV Signature 38 | View ↗ |
|
Non-Small Cell Lung Cancer (NSCLC)
NSCLC · Adenocarcinoma · Squamous Cell
|
249 | 7 | Oncogenic Driver Signaling 141Immune Microenvironment 40Histotype Lineage 20Stromal / Angiogenesis 17Proliferation 13DNA Damage / HRD 14Metabolism / Stress 9 | View ↗ |
|
Ovarian Cancer
HGSOC · LGSC · Clear Cell
|
221 | 7 | Tumor Intrinsic Signaling 65Immune Microenvironment 61Ovarian Tumor Cell States 41Peritoneal Metastasis 39PARPi / Platinum Resistance 36Stromal / Angiogenesis 32Proliferation / DNA Repair 26 | View ↗ |
|
Pancreatic Cancer (PDAC)
PDAC · Acinar Cell Carcinoma · Resectable / Locally Advanced / Metastatic
|
196 | 7 | KRAS / RAS Signaling 127Desmoplastic Stroma 27Immune Microenvironment 28Tumor Cell States 3DDR / HRD 10Metabolic Reprogramming 1EMT / Invasion 7 | View ↗ |
|
Prostate Cancer
Localized PCa · CRPC · CRPC-NE
|
283 | 7 | AR Pathway & Steroidogenesis 61DNA Damage / HRD 41Immune Microenvironment 55Bone Niche / Stroma 41Proliferation / Cell Cycle 33Lipid / Metabolism 33Cell State / PSMA 36 | View ↗ |
| Autoimmune / Neuroimmune 1 panel | ||||
|
Pediatric Rheumatology
JIA · pSLE · JDM
|
306 | 7 | Innate Immune Activation & IFN Signaling 64Adaptive Lymphocyte Programs 69Cytokine & JAK-STAT Signaling 61Stromal / Fibroblast & Tissue Remodeling 33Immune Regulation & Tolerance 42Complement & Autoantibody Biology 35Cell Activation / Co-stimulation & Trafficking 51 | View ↗ |
| Cross-Indication Applications 4 panels | ||||
|
CAR-T Cell Therapy
CD19 · BCMA · GD2
|
152 | 7 | CAR-T Product Identity 56Target Antigen on Tumor 37Persistence & Fitness 37TME Resistance 33Manufacturing QC 21Allo / Donor 16CRS & ICANS Risk 7 | View ↗ |
|
Drug Resistance Mechanisms
Pan-cancer · Targeted therapy · Chemotherapy
|
252 | 7 | RTK & Bypass Signaling 59DNA Repair & Therapy Resistance 49Apoptosis & Survival Escape 30Lineage Plasticity & Switching 47Immune Checkpoint Resistance 43Metabolic & Microenvironmental 30Senescence & Ferroptosis 30 | View ↗ |
|
Immunotherapy (IO) Response
Pan-solid tumor · PD-1/PD-L1 / CTLA-4 / LAG-3 / TIM-3 / TIGIT · All ICI-approved indications
|
221 | 7 | T Cell Identity & Exhaustion 118Checkpoint Ligands & Antigen Presentation 40Myeloid & NK States 48TLS & B Cell Programs 31IFN Signaling & TIS Score 28DNA Damage / TMB / MSI 22Metabolic Immune Escape 28 | View ↗ |
|
Tumor Microenvironment (TME)
Pan-cancer TME profiling · Hot / Cold / Excluded tumors · All solid tumor indications
|
247 | 7 | Myeloid Cell States 86T & NK Lymphocyte States 65B Cell & TLS 29CAF Subtypes & Stroma 40Tumor Cell States & Plasticity 49Complement & Innate Sensing 22Angiogenesis & Lymphangiogenesis 25 | View ↗ |
ⓘ Gene counts reflect unique genes per panel. Per-category counts may sum to a higher
number as select genes appear in more than one functional category.